Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Vitamin D receptor gene polymorphisms role in COVID‐19 severity: Results of a Mexican patients’ cohort

Ochoa-Ramírez et al., International Journal of Immunogenetics, doi:10.1111/iji.12674
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 78 treatments. c19early.org
Retrospective 292 COVID-19 patients finding that haplotype TC of the FokI and TaqI vitamin D receptor (VDR) gene polymorphisms was associated with an increased risk of critical COVID-19.
Ochoa-Ramírez et al., 28 Apr 2024, peer-reviewed, 6 authors.
This PaperVitamin DAll
{ 'indexed': {'date-parts': [[2024, 4, 30]], 'date-time': '2024-04-30T00:30:37Z', 'timestamp': 1714437037969}, 'reference-count': 22, 'publisher': 'Wiley', 'license': [ { 'start': { 'date-parts': [[2024, 4, 28]], 'date-time': '2024-04-28T00:00:00Z', 'timestamp': 1714262400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Vitamin D status has been involved with coronavirus ' 'disease 19 (COVID‐19) severity. This may be mediated by vitamin D metabolism regulatory ' 'genes. Of interest is the vitamin D receptor (VDR) gene, which has been previously associated ' 'with other inflammatory and respiratory diseases. In order to investigate the role of VDR ' 'gene polymorphisms in COVID‐19 severity and outcome, a total of 292 COVID‐19 patients were ' 'classified according to severity in moderate (<jats:italic>n</jats:italic>\xa0=\xa056), ' 'severe (<jats:italic>n</jats:italic>\xa0=\xa089) and critical ' '(<jats:italic>n</jats:italic>\xa0=\xa0147) and, according to outcome in survivor ' '(<jats:italic>n</jats:italic>\xa0=\xa0163) and deceased (<jats:italic>n</jats:italic>\xa0=\xa0' '129), and analysed for <jats:italic>Fok</jats:italic>I and <jats:italic>Taq</jats:italic>I ' 'VDR gene polymorphisms by polymerase chain reaction‐based restriction enzyme digestion. The ' '<jats:italic>Fok</jats:italic>I and <jats:italic>Taq</jats:italic>I single nucleotide ' 'polymorphisms (SNPs) were not associated with COVID‐19 severity or mortality individually but ' 'when analysed by haplotype, TC was associated with an increased risk of presenting critical ' 'COVID‐19. Additionally, <jats:italic>Fok</jats:italic>I CT genotype was more frequent in ' 'COVID‐19 patients with hypertension, and T allele carriers presented higher aspartate ' 'aminotransferase levels. Our results suggest a relationship between VDR ' '<jats:italic>Fok</jats:italic>I and <jats:italic>Taq</jats:italic>I SNPs and COVID‐19 ' 'severity in Mexican population. Although there are some previous reports of VDR polymorphisms ' 'in COVID‐19, this represents the first report in Latin American population. Further studies ' 'on other populations are encouraged.</jats:p>', 'DOI': '10.1111/iji.12674', 'type': 'journal-article', 'created': {'date-parts': [[2024, 4, 29]], 'date-time': '2024-04-29T04:04:25Z', 'timestamp': 1714363465000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Vitamin D receptor gene polymorphisms role in COVID‐19 severity: Results of a Mexican patients’ ' 'cohort', 'prefix': '10.1111', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5912-6500', 'authenticated-orcid': False, 'given': 'Luis Antonio', 'family': 'Ochoa‐Ramírez', 'sequence': 'first', 'affiliation': [ { 'name': 'Hospital General de Culiacán, Servicios de Salud de Sinaloa ' 'Culiacan Mexico'}]}, { 'given': 'Alba Lissy', 'family': 'Corona‐Angulo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Maestría en Ciencias Biomédicas, Facultad de Ciencias Químico ' 'Biológicas Culiacan Mexico'}]}, { 'given': 'Efrén Rafael', 'family': 'Ríos‐Burgueño', 'sequence': 'additional', 'affiliation': [ { 'name': 'Hospital General de Culiacán, Servicios de Salud de Sinaloa ' 'Culiacan Mexico'}, { 'name': 'Centro de Investigación y Docencia en Ciencias de la Salud ' 'Culiacan Mexico'}]}, { 'given': 'Jorge Guillermo', 'family': 'Sánchez‐Zazueta', 'sequence': 'additional', 'affiliation': [ { 'name': 'Facultad de Biología Universidad Autónoma de Sinaloa Culiacán ' 'Sinaloa Mexico'}]}, { 'ORCID': 'http://orcid.org/0000-0003-1251-3383', 'authenticated-orcid': False, 'given': 'Denisse Stephania', 'family': 'Becerra‐Loaiza', 'sequence': 'additional', 'affiliation': [ { 'name': 'Departamento de Aparatos y Sistemas II Universidad Autónoma de ' 'Guadalajara Zapopan Jalisco México'}]}, { 'given': 'Jesús Salvador', 'family': 'Velarde‐Félix', 'sequence': 'additional', 'affiliation': [ { 'name': 'Hospital General de Culiacán, Servicios de Salud de Sinaloa ' 'Culiacan Mexico'}, { 'name': 'Maestría en Ciencias Biomédicas, Facultad de Ciencias Químico ' 'Biológicas Culiacan Mexico'}, { 'name': 'Facultad de Biología Universidad Autónoma de Sinaloa Culiacán ' 'Sinaloa Mexico'}]}], 'member': '311', 'published-online': {'date-parts': [[2024, 4, 28]]}, 'reference': [ { 'key': 'e_1_2_9_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.meegid.2021.105098'}, {'key': 'e_1_2_9_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/genes13122346'}, {'key': 'e_1_2_9_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cen.14664'}, { 'key': 'e_1_2_9_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/biomedicines11020400'}, {'key': 'e_1_2_9_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41584‐023‐00944‐2'}, {'key': 'e_1_2_9_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1210/clinem/dgab892'}, {'key': 'e_1_2_9_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.17179/excli2022‐4976'}, {'key': 'e_1_2_9_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmjopen‐2022‐064058'}, {'key': 'e_1_2_9_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3892/etm.2023.11920'}, {'key': 'e_1_2_9_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fnut.2021.689419'}, { 'key': 'e_1_2_9_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1365‐2133.2012.11132.x'}, {'key': 'e_1_2_9_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ppul.22877'}, { 'key': 'e_1_2_9_14_1', 'unstructured': 'Mexico Government. (2021).Reporte de vigilancia genómica del virus ' 'SARS‐CoV‐2 en México.Mexico ' 'Government.https://coronavirus.gob.mx/wp‐content/uploads/2021/09/2021.08.30_ReporteVariantesCOVID‐2.pdf'}, {'key': 'e_1_2_9_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/advances/nmaa076'}, {'key': 'e_1_2_9_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/ijd.14508'}, { 'key': 'e_1_2_9_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.22034/iji.2022.92641.2162'}, {'key': 'e_1_2_9_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms21249626'}, {'key': 'e_1_2_9_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bcmd.2013.02.001'}, { 'key': 'e_1_2_9_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.arcmed.2023.03.006'}, { 'key': 'e_1_2_9_21_1', 'volume-title': 'Living guidance for clinical management of COVID‐19', 'author': 'World Health Organization (WHO)', 'year': '2021'}, {'key': 'e_1_2_9_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12016‐022‐08921‐5'}, { 'key': 'e_1_2_9_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/08820139.2019.1674325'}], 'container-title': 'International Journal of Immunogenetics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/iji.12674', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 29]], 'date-time': '2024-04-29T04:04:32Z', 'timestamp': 1714363472000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/iji.12674'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 28]]}, 'references-count': 22, 'alternative-id': ['10.1111/iji.12674'], 'URL': 'http://dx.doi.org/10.1111/iji.12674', 'relation': {}, 'ISSN': ['1744-3121', '1744-313X'], 'subject': [], 'container-title-short': 'Int J Immunogenetics', 'published': {'date-parts': [[2024, 4, 28]]}, 'assertion': [ { 'value': '2023-10-18', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-04-14', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2024-04-28', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit